Journal Article Research Support, Non-U.S. Gov't Epublish 14 citations
PubMed: 37328580 DOI: 10.1038/s41598-023-36874-y
Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.
Sci Rep 13(1):9802
Authors: Joanna Nizioł, Krzysztof Ossoliński, Aneta Płaza-Altamer, Artur Kołodziej, Anna Ossolińska, Tadeusz Ossoliński, Anna Nieczaj, Tomasz Ruman
Affiliations
- Faculty of Chemistry, Rzeszów University of Technology, 6 Powstańców Warszawy Ave. 35-959, Rzeszów, Poland.
- Department of Urology, John Paul II Hospital, Grunwaldzka 4 St. 36-100, Kolbuszowa, Poland.
- Faculty of Chemistry, Rzeszów University of Technology, 6 Powstańców Warszawy Ave. 35-959, Rzeszów, Poland.
- Doctoral School of Engineering and Technical Sciences at the Rzeszów University of Technology, 8 Powstańców Warszawy Ave. 35-959, Rzeszów, Poland.
Abstract
Bladder cancer (BC) is a common urological malignancy with a high probability of death and recurrence. Cystoscopy is used as a routine examination for diagnosis and following patient monitoring for recurrence. Repeated costly and intrusive treatments may discourage patients from having frequent follow-up screenings. Hence, exploring novel non-invasive ways to help identify recurrent and/or primary BC is critical. In this work, 200 human urine samples were profiled using ultra-high-performance liquid chromatography and ultra-high-resolution mass spectrometry (UHPLC-UHRMS) to uncover molecular markers differentiating BC from non-cancer controls (NCs). Univariate and multivariate statistical analyses with external validation identified metabolites that distinguish BC patients from NCs disease. More detailed divisions for the stage, grade, age, and gender are also discussed. Findings indicate that monitoring urine metabolites may provide a non-invasive and more straightforward diagnostic method for identifying BC and treating recurrent diseases.
MeSH
Urinary Bladder Neoplasms, Biomarkers, Metabolomics, Natural Science Disciplines
Cited by
- A Workflow for Meaningful Interpretation of Classification Results from Handheld Ambient Mass Spectrometry Analysis Probes. Int J Mol Sci, 2024
- The role of spectral characteristics of urine in bladder cancer diagnostics. Sci Rep, 2025
- Untargeted metabolomic profiling of serum and urine in kidney cancer: a non-invasive approach for biomarker discovery. Metabolomics, 2025
- Identification of Diagnostic Biomarkers for Colorectal Polyps Based on Noninvasive Urinary Metabolite Screening and Construction of a Nomogram. Cancer Med, 2025
- Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment. Int J Mol Sci, 2024
- Metabolomics, Genetics, and Environmental Factors: Intersecting Paths in Abdominal Aortic Aneurysm. Int J Mol Sci, 2025
- Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review. Int J Mol Sci, 2024